Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (104)
January 26, 2009
-
Maurer's Healthcare Insight (103)
January 5, 2009
-
Maurer's Healthcare Insight (102)
December 8, 2008
-
Maurer's Healthcare Insight (101)
December 1, 2008
-
Maurer's Healthcare Insight (100)
October 27, 2008
-
Maurer's Healthcare Insight (99)
September 29, 2008
-
Maurer's Healthcare Insight (98)
August 25, 2008
-
Maurer's Healthcare Insight (97)
July 28, 2008
-
Maurer's Healthcare Insight (96)
June 23, 2008
-
Maurer's Healthcare Insight (95)
May 19, 2008
-
Maurer's Healthcare Insight (94)
March 10, 2008
-
Maurer's Healthcare Insight (93)
February 18, 2008
-
Maurer's Healthcare Insight (92)
January 21, 2008
-
Maurer's Healthcare Insight (91)
December 24, 2007
-
Maurer's Healthcare Insight (90)
November 5, 2007
-
Maurer's Healthcare Insight (89)
October 8, 2007
-
Maurer's Healthcare Insight (88)
August 6, 2007
-
Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer
June 4, 2007
-
Maurer's Healthcare Insight (86)
May 28, 2007
-
Maurer's Healthcare Insight (85)
April 16, 2007
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…